The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The impact of cytogenetic risk on outcomes of haploidentical transplantation in R/R AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses the relationship between HLA mismatching and graft-versus-leukemia (GvL) effect in haploidentical transplantation in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). First, Prof. Nagler explains the correlation observed between graft-versus-host disease (GvHD) and GvL in sibling and unrelated transplantation. Following this, Prof. Nagler highlights the impact of measurable residual disease (MRD) and cytogenetic risk on the efficacy of haploidentical transplant, and recent studies in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
